 NEW YORK and LONDON, May 11, 2022 GLOBE NEWSWIRE -- Akari Therapeutics, Plc Nasdaq: AKTX, a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced that two posters will be presented at the American Thoracic Society ATS 2022 Annual Meeting reporting results from the CORONET and CASCADE studies in patients with COVID-19 pneumonia. 